8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 1/22

Cancer: Catalytic

Tessy LópezUniversidad Autónoma Metropolitana

National Institute of Neurology andNeurosurgery

tessy3@prodigy.net.mx

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 2/22

What is cancer?

Is a term used for diseases in which abnormal cells dividewithout control and are able to invade other tissues. Cancer cells can spread to other parts of the body through the blood

and lymphatic systems (metastasize).

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 3/22

ClassificaThis classification describes

the type of tissue in which thecancer cells begin to develop.

•

Adenocarcinoma - originates intissue

• Glioma – glial tissue

• Carcinoma– epithelial tissue

• Leukemia– blood cells

• Lymphoma– lymphatic tissue

• Myeloma– bone marrow

• –

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 4/22

Most cancers are named for

the organ or type of cell inwhich they begin.

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 5/22

Glioblastoma Multiforme(GBM) are 35% brain cancer,

according to the OMSstatistics. Those are theprimary and more frequenttumors of the Central

Nervous System (CNS).

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 6/22

NANOMEDICINE AND

Nanotechnology hasbeen applied in all

therapeutic areas of medicine.

The most extensiveinvestigations are in

cancer.

Nanoparticles can

deliver chemotherapydrugs directly to tumorcells and then give off asignal after the cells are

destroyed. Drugs

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 7/22

•

The treatment of Central NervousSystem (CNS) is difficult due to theBlood Brain Barrier (BBB) cross.

•

Only low molecular weightmolecules, liposolubles, and anypeptidic compounds cross the BBB.

 

Passive diffusion or specific

MECHANISM

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 8/22

Local application or direct tumor injection of cytotoxic drugs has been proposed as a

technique to use 100% .

Systemic exposure and non-target organ

toxicity is minimized 

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 9/22

Gliadel: Drug delivery systemof carmustine in CNS to GBM

PRODUCT IN THE MARQUET

Only release thechemotherapy

during 10 days.

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 10/22

We have an alternative drug deliveryWe have an alternative drug delivery

System. This deliver during six monthsSystem. This deliver during six months

thetheFollowing drugs: Carmustine andFollowing drugs: Carmustine andRelease from TiO2 Release from SiO2

Tumor with C6

cancer cells Sol-gel device with drug

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 11/22

Catalytic Nanomedicineis a new wa to treat

We made a catalytic processin the nucleotides of the

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 12/22

BIO-CATALYST UAM-INNN

1. Cis Pt/SBA-15

2. Pt(acac)2/SiO2

3. Pt(acac)2/TiO2

4. H2PtCl6/SiO2

5. H2PtCl

6/TiO

26. Temozolomida/TiO2

7. (NH2)4Cl2Pt/ SiO2

8. Doxorubicina/SiO2

9. Metotrexato/SiO2

10.Cis-diamindicloro-Platino (II)B

11.Cis-diamindicloro-Platino (II)A

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 13/22

CHARACTERIZ

Pt/SiO2

640m2/g

Particle size of theSupport = 30 nmParticle size of thePlatinum = 3-5 nm

Brönsted andLewis acid sites

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 14/22

Pt/TiOC6 cellular model wasused to form

a tumor of 5 cm of diameter.

n = 70

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 15/22

Control Platinum complex

Titania Titania-Platinum

Control Platinum complex

Titania Titania-Platinum

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 16/22

0

10

20

30

40

50

60

CONTROL Pt TiO2 TiO2-Pt

   T  u  m  o  r  a   l  w  e   i  g

   t   h   (  g  r   )

*

*p=0.03 when compared with control

Tumoral weight reduction

24.6%

43.4%55.7%

Average tumor size of C6 glioma in rats after treatment

0

10

20

30

40

50

60

CONTROL Pt TiO2 TiO2-Pt

   T  u  m  o  r  a   l  w  e   i  g

   t   h   (  g  r   )

*

*p=0.03 when compared with control

Tumoral weight reduction

24.6%

43.4%55.7%

Average tumor size of C6 glioma in rats after treatment

96%

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 17/22

Particl

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 18/22

• A significant growth inhibitionwas observed in animal treated

with Platinum-titania .• The existence of stronger

electron-acceptor centers (Ti4+ 

and Ti3+

ions) that can coordinatewith basic molecules placed atDNA and promoted the apoptosismechanism.

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 19/22

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 20/22

 

t=0 t= 3 t=5 t=10

Degradation of DNA studies withour different

Nanoparticles: control release

7

t=72

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 21/22

8/14/2019 Nanotechnology 2008

http://slidepdf.com/reader/full/nanotechnology-2008 22/22Thank you